J. B. Chemicals & Pharmaceuticals Limited (JBCHEPHARM.NS)
INR 1576.8
(-2.21%)
INR 1576.8
(-2.21%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 10.7 Billion INR | -0.25% |
| 2022 | 10.73 Billion INR | 129.0% |
| 2021 | 4.68 Billion INR | 10.39% |
| 2020 | 4.24 Billion INR | 13.08% |
| 2019 | 3.75 Billion INR | 21.91% |
| 2018 | 3.08 Billion INR | -3.89% |
| 2017 | 3.2 Billion INR | 4.01% |
| 2016 | 3.08 Billion INR | -33.3% |
| 2015 | 4.62 Billion INR | -6.16% |
| 2014 | 4.92 Billion INR | 59.76% |
| 2013 | 3.08 Billion INR | 10.1% |
| 2012 | 2.79 Billion INR | 22.86% |
| 2011 | 2.27 Billion INR | -25.98% |
| 2010 | 3.07 Billion INR | 14.5% |
| 2009 | 2.68 Billion INR | -3.09% |
| 2008 | 2.77 Billion INR | -3.77% |
| 2007 | 2.88 Billion INR | -1.89% |
| 2006 | 2.93 Billion INR | 68.0% |
| 2005 | 1.74 Billion INR | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 FY | 10.7 Billion INR | -0.25% |
| 2023 Q1 | - INR | -100.0% |
| 2023 Q3 | - INR | -100.0% |
| 2023 Q2 | 10.82 Billion INR | 0.0% |
| 2023 Q4 | 10.7 Billion INR | 0.0% |
| 2022 Q4 | 10.73 Billion INR | 0.0% |
| 2022 Q3 | - INR | -100.0% |
| 2022 Q2 | 8.91 Billion INR | 0.0% |
| 2022 Q1 | - INR | -100.0% |
| 2022 FY | 10.73 Billion INR | 129.0% |
| 2021 Q1 | - INR | -100.0% |
| 2021 FY | 4.68 Billion INR | 10.39% |
| 2021 Q3 | - INR | -100.0% |
| 2021 Q4 | 4.68 Billion INR | 0.0% |
| 2021 Q2 | 4.33 Billion INR | 0.0% |
| 2020 Q3 | - INR | -100.0% |
| 2020 Q2 | 4.24 Billion INR | 0.0% |
| 2020 Q1 | - INR | -100.0% |
| 2020 FY | 4.24 Billion INR | 13.08% |
| 2020 Q4 | 4.24 Billion INR | 0.0% |
| 2019 Q4 | 3.75 Billion INR | 0.0% |
| 2019 Q2 | 3.69 Billion INR | 0.0% |
| 2019 Q1 | - INR | -100.0% |
| 2019 FY | 3.75 Billion INR | 21.91% |
| 2019 Q3 | - INR | -100.0% |
| 2018 FY | 3.08 Billion INR | -3.89% |
| 2018 Q4 | 3.08 Billion INR | 0.0% |
| 2018 Q1 | - INR | 0.0% |
| 2017 FY | 3.2 Billion INR | 4.01% |
| 2016 Q4 | 3.08 Billion INR | 0.0% |
| 2016 FY | 3.08 Billion INR | -33.3% |
| 2015 FY | 4.62 Billion INR | -6.16% |
| 2015 Q4 | 4.62 Billion INR | 0.0% |
| 2014 FY | 4.92 Billion INR | 59.76% |
| 2013 FY | 3.08 Billion INR | 10.1% |
| 2012 FY | 2.79 Billion INR | 22.86% |
| 2011 FY | 2.27 Billion INR | -25.98% |
| 2010 FY | 3.07 Billion INR | 14.5% |
| 2009 FY | 2.68 Billion INR | -3.09% |
| 2008 FY | 2.77 Billion INR | -3.77% |
| 2007 FY | 2.88 Billion INR | -1.89% |
| 2006 FY | 2.93 Billion INR | 68.0% |
| 2005 FY | 1.74 Billion INR | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Amrutanjan Health Care Limited | 783.82 Million INR | -1266.123% |
| Biofil Chemicals and Pharmaceuticals Limited | 288.79 Million INR | -3607.769% |
| Caplin Point Laboratories Limited | 3.5 Billion INR | -205.454% |
| FDC Limited | 3.7 Billion INR | -188.687% |
| Gufic Biosciences Limited | 5.59 Billion INR | -91.221% |
| Hikal Limited | 12.99 Billion INR | 17.598% |
| Ind-Swift Laboratories Limited | 2.28 Billion INR | -367.708% |
| IOL Chemicals and Pharmaceuticals Limited | 6.32 Billion INR | -69.192% |
| Kilitch Drugs (India) Limited | 643.88 Million INR | -1563.035% |
| Medico Remedies Limited | 438.24 Million INR | -2343.388% |
| Nectar Lifesciences Limited | 11.21 Billion INR | 4.547% |
| Par Drugs and Chemicals Limited | 159.79 Million INR | -6601.254% |
| RPG Life Sciences Limited | 1.38 Billion INR | -675.83% |
| Sequent Scientific Limited | 8.27 Billion INR | -29.414% |
| Shilpa Medicare Limited | 12.93 Billion INR | 17.201% |
| Sigachi Industries Limited | 2.53 Billion INR | -323.03% |
| Themis Medicare Limited | 1.88 Billion INR | -467.308% |
| Unichem Laboratories Limited | 8.06 Billion INR | -32.701% |
| Venus Remedies Limited | 1.39 Billion INR | -668.811% |
| Wanbury Limited | 3.15 Billion INR | -239.342% |
| ZIM Laboratories Limited | 2.08 Billion INR | -414.619% |
| Lupin Limited | 96.23 Billion INR | 88.873% |
| Innova Captab Limited | 4.89 Billion INR | -118.536% |
| Ind-Swift Limited | 13.45 Billion INR | 20.404% |
| Bajaj HealthCare Limited | 4.86 Billion INR | -119.982% |
| Aurobindo Pharma Limited | 152.2 Billion INR | 92.965% |
| Solara Active Pharma Sciences Limited | 14.09 Billion INR | 24.013% |
| AstraZeneca Pharma India Limited | 3.66 Billion INR | -192.48% |
| Mangalam Drugs & Organics Limited | 1.97 Billion INR | -441.818% |
| Morepen Laboratories Limited | 4.45 Billion INR | -140.101% |
| Laurus Labs Limited | 42.71 Billion INR | 74.931% |
| Aarti Drugs Limited | 11.5 Billion INR | 6.919% |
| Glenmark Life Sciences Limited | 5.18 Billion INR | -106.682% |
| Alembic Limited | 1.43 Billion INR | -647.713% |
| Alembic Pharmaceuticals Limited | 16.27 Billion INR | 34.201% |
| Glenmark Pharmaceuticals Limited | 65.11 Billion INR | 83.554% |
| Vaishali Pharma Limited | 371.16 Million INR | -2784.986% |
| Aarti Pharmalabs Limited | 8.25 Billion INR | -29.783% |
| Jagsonpal Pharmaceuticals Limited | 296.76 Million INR | -3508.303% |
| Jubilant Pharmova Limited | 61.27 Billion INR | 82.524% |
| Eris Lifesciences Limited | 38.26 Billion INR | 72.018% |
| Windlas Biotech Limited | 1.76 Billion INR | -507.477% |
| Sun Pharmaceutical Industries Limited | 183.56 Billion INR | 94.167% |
| Lincoln Pharmaceuticals Limited | 1.07 Billion INR | -896.515% |
| Orchid Pharma Limited | 3.84 Billion INR | -178.558% |
| Albert David Limited | 1.15 Billion INR | -831.045% |
| Hester Biosciences Limited | 3.59 Billion INR | -197.881% |
| Sakar Healthcare Limited | 1.26 Billion INR | -747.635% |
| Suven Pharmaceuticals Limited | 2.03 Billion INR | -426.391% |
| Procter & Gamble Health Limited | 2.56 Billion INR | -318.085% |
| Divi's Laboratories Limited | 18.99 Billion INR | 43.612% |
| Mankind Pharma Limited | 23.87 Billion INR | 55.149% |
| Neuland Laboratories Limited | 5.49 Billion INR | -94.742% |
| Zydus Lifesciences Limited | 71.79 Billion INR | 85.085% |
| Wockhardt Limited | 39.87 Billion INR | 73.143% |
| Bal Pharma Limited | 2.51 Billion INR | -326.397% |
| Dr. Reddy's Laboratories Limited | 106.96 Billion INR | 89.99% |
| Bliss GVS Pharma Limited | 2.1 Billion INR | -407.765% |
| Alkem Laboratories Limited | 48.6 Billion INR | 77.969% |
| Valiant Laboratories Limited | 1.05 Billion INR | -911.849% |
| Ajanta Pharma Limited | 10.71 Billion INR | 0.021% |
| Bafna Pharmaceuticals Limited | 652.27 Million INR | -1541.629% |
| Aarey Drugs & Pharmaceuticals Limited | 1.72 Billion INR | -521.767% |
| Granules India Limited | 22.95 Billion INR | 53.351% |
| Medicamen Biotech Limited | 940.36 Million INR | -1038.704% |
| Ipca Laboratories Limited | 33.74 Billion INR | 68.266% |
| Brooks Laboratories Limited | 248.6 Million INR | -4207.304% |
| Syncom Formulations (India) Limited | 1.16 Billion INR | -818.975% |
| Piramal Enterprises Limited | 560.47 Billion INR | 98.089% |
| Torrent Pharmaceuticals Limited | 82.05 Billion INR | 86.949% |
| NATCO Pharma Limited | 10.53 Billion INR | -1.671% |
| Suven Life Sciences Limited | 148.62 Million INR | -7104.904% |
| Krebs Biochemicals & Industries Limited | 2.97 Billion INR | -260.064% |
| Strides Pharma Science Limited | 37.68 Billion INR | 71.582% |
| Indoco Remedies Limited | 10.34 Billion INR | -3.536% |
| Alpa Laboratories Limited | 307.12 Million INR | -3386.562% |
| Lasa Supergenerics Limited | 541.92 Million INR | -1875.919% |
| Sun Pharma Advanced Research Company Limited | 3.89 Billion INR | -175.065% |